MetLife Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.03M | Buy |
204,080
+56,073
| +38% | +$284K | 0.01% | 1297 |
|
|
2025
Q1 | $783K | Sell |
148,007
-1,801
| -1% | -$9.53K | ﹤0.01% | 1483 |
|
|
2024
Q4 | $1.01M | Buy |
149,808
+13,267
| +10% | +$89.7K | 0.01% | 1407 |
|
|
2024
Q3 | $900K | Buy |
136,541
+16,405
| +14% | +$108K | 0.01% | 1453 |
|
|
2024
Q2 | $901K | Buy |
120,136
+47,975
| +66% | +$360K | 0.01% | 1399 |
|
|
2024
Q1 | $719K | Hold |
72,161
| – | – | ﹤0.01% | 1485 |
|
|
2023
Q4 | $712K | Hold |
72,161
| – | – | 0.01% | 1491 |
|
|
2023
Q3 | $552K | Hold |
72,161
| – | – | ﹤0.01% | 1571 |
|
|
2023
Q2 | $539K | Hold |
72,161
| – | – | ﹤0.01% | 1649 |
|
|
2023
Q1 | $481K | Hold |
72,161
| – | – | ﹤0.01% | 1670 |
|
|
2022
Q4 | $556K | Hold |
72,161
| – | – | ﹤0.01% | 1574 |
|
|
2022
Q3 | $768K | Hold |
72,161
| – | – | 0.01% | 1328 |
|
|
2022
Q2 | $587K | Buy |
72,161
+8,126
| +13% | +$66.1K | ﹤0.01% | 1551 |
|
|
2022
Q1 | $458K | Buy |
64,035
+22,833
| +55% | +$163K | ﹤0.01% | 1826 |
|
|
2021
Q4 | $706K | Buy |
41,202
+30,451
| +283% | +$522K | 0.01% | 1302 |
|
|
2021
Q3 | $247K | Buy |
10,751
+2,043
| +23% | +$47K | ﹤0.01% | 1953 |
|
|
2021
Q2 | $318K | Buy |
+8,708
| New | +$318K | ﹤0.01% | 1848 |
|